Comparing Two Approaches to Identify Individuals with Severe Asthma in United States Claims Data.

IF 2.4 4区 医学 Q3 PHARMACOLOGY & PHARMACY
Julie Barberio, Xinyu Li, Sarah-Jo Sinnott
{"title":"Comparing Two Approaches to Identify Individuals with Severe Asthma in United States Claims Data.","authors":"Julie Barberio, Xinyu Li, Sarah-Jo Sinnott","doi":"10.1002/pds.70220","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Given the increased likelihood for individuals with severe asthma to experience comorbidities, disease complications, emergency room visits, and hospitalizations, the ability to stratify asthma populations on severity is often important. Although pharmacoepidemiologic studies using administrative healthcare databases sometimes categorize asthma severity, there is no consensus on an approach.</p><p><strong>Methods: </strong>Individuals with asthma (≥ 2 ICD-10-CM diagnosis codes J45) aged ≥ 6 years were identified in Optum's de-identified Clinformatics Data Mart Database between January 2017 and November 2023. Severe asthma was inferred, consistent with the Global Initiative for Asthma (GINA), from prescription claims for high-dose inhaled corticosteroids (ICS) in combination with long-acting beta-agonists (LABA) (Step 5 treatment). Two algorithm versions were employed to isolate the impact of dose estimation methods: (1) the \"code-based method\" considered high-dose ICS-LABA to be an inhaler property and defined severe asthma based on claims for ICS-LABA from our pre-determined list; (2) the \"calculation-based method\" considered high-dose ICS-LABA to be a regimen property and defined severe asthma based on derived patient-level average daily dose.</p><p><strong>Results: </strong>A total of 1 221 732 individuals with asthma were identified, 3.1% of which were severe by the code-based method and 4.2% by the calculation-based method. Both methods appeared to be consistent with the benchmark cited by GINA (3.7%). No meaningful differences were observed in the characteristics of the cohorts. 27% of calculation-based individuals with severe asthma were not captured by the code-based method.</p><p><strong>Conclusions: </strong>Estimating patient-level average daily ICS dose based on prescription claims using either a code-based or a calculation-based algorithm appears to be a reasonable method to identify individuals with severe asthma. The discrepancy between methods suggests that physician instructions sometimes vary from recommended administration instructions. Future work will validate these algorithms using electronic medical records.</p>","PeriodicalId":19782,"journal":{"name":"Pharmacoepidemiology and Drug Safety","volume":"34 9","pages":"e70220"},"PeriodicalIF":2.4000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacoepidemiology and Drug Safety","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pds.70220","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Given the increased likelihood for individuals with severe asthma to experience comorbidities, disease complications, emergency room visits, and hospitalizations, the ability to stratify asthma populations on severity is often important. Although pharmacoepidemiologic studies using administrative healthcare databases sometimes categorize asthma severity, there is no consensus on an approach.

Methods: Individuals with asthma (≥ 2 ICD-10-CM diagnosis codes J45) aged ≥ 6 years were identified in Optum's de-identified Clinformatics Data Mart Database between January 2017 and November 2023. Severe asthma was inferred, consistent with the Global Initiative for Asthma (GINA), from prescription claims for high-dose inhaled corticosteroids (ICS) in combination with long-acting beta-agonists (LABA) (Step 5 treatment). Two algorithm versions were employed to isolate the impact of dose estimation methods: (1) the "code-based method" considered high-dose ICS-LABA to be an inhaler property and defined severe asthma based on claims for ICS-LABA from our pre-determined list; (2) the "calculation-based method" considered high-dose ICS-LABA to be a regimen property and defined severe asthma based on derived patient-level average daily dose.

Results: A total of 1 221 732 individuals with asthma were identified, 3.1% of which were severe by the code-based method and 4.2% by the calculation-based method. Both methods appeared to be consistent with the benchmark cited by GINA (3.7%). No meaningful differences were observed in the characteristics of the cohorts. 27% of calculation-based individuals with severe asthma were not captured by the code-based method.

Conclusions: Estimating patient-level average daily ICS dose based on prescription claims using either a code-based or a calculation-based algorithm appears to be a reasonable method to identify individuals with severe asthma. The discrepancy between methods suggests that physician instructions sometimes vary from recommended administration instructions. Future work will validate these algorithms using electronic medical records.

比较两种方法来识别美国索赔数据中的严重哮喘患者。
目的:鉴于严重哮喘患者出现合并症、疾病并发症、急诊室就诊和住院的可能性增加,根据严重程度对哮喘人群进行分层的能力通常很重要。虽然使用行政卫生保健数据库的药物流行病学研究有时会对哮喘严重程度进行分类,但在一种方法上没有达成共识。方法:在2017年1月至2023年11月期间,在Optum的去识别临床数据集市数据库中识别年龄≥6岁的哮喘患者(≥2例ICD-10-CM诊断代码J45)。根据全球哮喘倡议(GINA),从大剂量吸入皮质类固醇(ICS)联合长效β激动剂(LABA)(第5步治疗)的处方声明中推断出严重哮喘。采用了两种算法版本来隔离剂量估计方法的影响:(1)“基于代码的方法”将高剂量ICS-LABA视为吸入器特性,并根据我们预先确定的ICS-LABA清单中的声明定义严重哮喘;(2)“基于计算的方法”将高剂量ICS-LABA视为一种方案特性,并根据导出的患者水平平均日剂量来定义严重哮喘。结果:共发现1 221 732例哮喘患者,其中基于代码的方法为重症,基于计算的方法为4.2%。两种方法均符合GINA引用的基准(3.7%)。在队列特征方面没有观察到有意义的差异。27%的基于计算的严重哮喘患者没有被基于代码的方法捕获。结论:基于处方声明,使用基于代码或基于计算的算法估计患者水平的平均每日ICS剂量似乎是识别严重哮喘个体的合理方法。方法之间的差异表明医生的指导有时与推荐的给药指导不同。未来的工作将使用电子病历验证这些算法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
7.70%
发文量
173
审稿时长
3 months
期刊介绍: The aim of Pharmacoepidemiology and Drug Safety is to provide an international forum for the communication and evaluation of data, methods and opinion in the discipline of pharmacoepidemiology. The Journal publishes peer-reviewed reports of original research, invited reviews and a variety of guest editorials and commentaries embracing scientific, medical, statistical, legal and economic aspects of pharmacoepidemiology and post-marketing surveillance of drug safety. Appropriate material in these categories may also be considered for publication as a Brief Report. Particular areas of interest include: design, analysis, results, and interpretation of studies looking at the benefit or safety of specific pharmaceuticals, biologics, or medical devices, including studies in pharmacovigilance, postmarketing surveillance, pharmacoeconomics, patient safety, molecular pharmacoepidemiology, or any other study within the broad field of pharmacoepidemiology; comparative effectiveness research relating to pharmaceuticals, biologics, and medical devices. Comparative effectiveness research is the generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition, as these methods are truly used in the real world; methodologic contributions of relevance to pharmacoepidemiology, whether original contributions, reviews of existing methods, or tutorials for how to apply the methods of pharmacoepidemiology; assessments of harm versus benefit in drug therapy; patterns of drug utilization; relationships between pharmacoepidemiology and the formulation and interpretation of regulatory guidelines; evaluations of risk management plans and programmes relating to pharmaceuticals, biologics and medical devices.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信